Zivo Bioscience, Inc. Announces Pricing of $ 13.8

KEEGO HARBOR, Mich., May 27, 2021 (GLOBE NEWSWIRE) – Zivo Bioscience, Inc. (OTCMKTS: ZIVO), a biotechnology / agtech R&D company engaged in the development and commercialization of nutritional / nutraceutical product candidates originally derived from Proprietary Algae Cultures, today announced the price of its subscribed public offering of 2,760,000 units at a public price of $ 5.00 per unit. Each Unit to be issued under the Offer consists of one Common Share and a Warrant to purchase one Common Share at an exercise price of $ 5.50. The common shares and the warrants are immediately separable and will be issued separately. The common shares and warrants are expected to begin trading on the Nasdaq Capital Market on May 28, 2021, under the symbols “ZIVO” and “ZIVOW”, respectively. ZIVO expects to receive gross proceeds of $ 13.8 million, before the deduction of subscription discounts and estimated commissions and other costs related to the offering. As part of the offer, the Company will reverse split its issued and outstanding common shares at a ratio of 1 to 80. The reverse stock split is expected to be effective at 12:01 am Eastern Time. , May 28, 2021. The share numbers and pricing information in this release have been adjusted to give effect to the Reverse Stock Split.

ZIVO has granted the underwriters a 45-day option to purchase up to 414,000 additional common shares and / or 414,000 additional warrants at the public offering price to cover over-allotments, if any. The offer is expected to close on June 2, 2021, subject to customary closing conditions.

Maxim Group LLC acts as the senior manager of the books management, and Joseph Gunnar & Co., LLC acts as the co-manager of the books for the offering.

The offering is being made in accordance with the company’s registration statement on Form S-1 (File No. 333-251221), as amended, previously filed and subsequently declared effective by the Securities and Exchange Commission (“ DRY”). A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering, when available, may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, nor any sale of such securities in any state or jurisdiction where such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Zivo Bioscience, Inc.

Zivo Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotechnology / agtech company engaged in the study of the health and nutritional benefits of bioactive compounds derived from its proprietary algae cultures, and the development of compounds natural bioactives for use as dietary supplements and food ingredients, as well as candidates of biological and synthetic origin for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of modulation of autoimmune and inflammatory response.

Forward-looking statements

Except for all historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, between others, statements concerning the planned closing of the public offer subscribed by the company. While ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that such statements are based on a combination of facts and factors currently known to us and our expectations for the future, of which we cannot be certain. . Our actual future results may be materially different from what we expect due to factors largely beyond our control, including the risks that the offering will not be closed on time or not at all, the risks that our strategic partnerships do not facilitate the marketing or market acceptance of our products; the risks that our products will not be ready for market on a timely basis or not at all; the risks that our products will not perform as expected based on the results of our preclinical and clinical trials; our ability to raise additional funds; the uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; clinical trial results, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under “Risk Factors” in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and ZIVO assumes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available at the time. to come up.

Contact:
Investor Relations
CORE IR
516-222-2560
[email protected]

Media
CORE IR
Jules Abraham
917-885-7378
[email protected]

About Jason Norton

Check Also

Spectrum Group International Announces Consent Results

COSTA MESA, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) – Spectrum Group International, Inc. (OTC Pink: …

Leave a Reply

Your email address will not be published. Required fields are marked *